Logo

People in the News: Art Krieg, Philip Ranker, Richard Ho

Jan 16, 2014
Premium

Art Krieg has been named as CSO of RNA drug developer Sarepta Therapeutics.

Krieg previously served as CEO of gene-activation firm Rana Therapeutics, which he cofounded in 2011. Before that, he led Pfizer's oligonucleotide therapeutics unit.

He remains a Rana senior advisor and scientific advisory board member.

Troubled RNAi drug firm Marina Biotech disclosed this month the resignations of CFO Philip Ranker and executive VP of research and development Richard Ho.

The departures come after Marina shut down essentially all of its operations in mid-2012 due to lack of funding.

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
Marina
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.